共 133 条
[1]
Evers S(2009)EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force Eur J Neurol 16 968-981
[2]
Áfra J(2015)Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study Lancet Neurol 14 1081-1090
[3]
Frese A(2014)Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study Lancet Neurol 13 885-892
[4]
Goadsby PJ(2014)Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial Lancet Neurol 13 1100-1107
[5]
Linde M(2016)Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial Lancet Neurol 15 382-390
[6]
May A(2017)Erenumab (AMG 334) in episodic migraine Neurology 89 1237-1243
[7]
Bigal ME(2016)Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine Pain 157 2773-2781
[8]
Dodick DW(2010)Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura Cephalalgia 30 1179-1186
[9]
Rapoport AM(2002)CGRP may play a causative role in migraine Cephalalgia 22 54-61
[10]
Silberstein SD(2011)Evidence for a vascular factor in migraine Ann Neurol 69 635-645